

**CENTRAL PHARMACEUTICAL  
JOINT STOCK COMPANY NO2**

**SOCIALIST REPUBLIC OF VIETNAM**  
**Independence – Freedom – Happiness**

No.: 15 / CV-DPTU2

Hanoi, date 14 January 2026

V/v: Re: Explanation of profit fluctuations in  
business operations of the 4<sup>th</sup> Quarter 2025  
Financial Statements with a variance of over  
10% compared to the same period last year

**To: - The State Securities Commission**

**- The Hanoi Stock Exchange**

Central Pharmaceutical Joint Stock Company No.2 (Stock code **DP2**) sends our respectful greetings and expresses our gratitude for your attention to our Company.

Implementing Circular No. 96/2020/TT-BTC dated November 16, 2020, issued by the Ministry of Finance, providing guidelines on information disclosure on the securities market:

In the Financial Statements for the 4<sup>th</sup> Quarter of 2025 dated January \_\_, 2026 of Central Pharmaceutical Joint Stock Company No.2, profit after corporate income tax for the current period amounted to VND -4,913,922,349, compared to VND 2,025,190,631 for the same period of the previous year.

DP2 hereby explains the profit performance from production and business activities as follows:

- In the 4<sup>th</sup> Quarter of 2025, the Company made efforts to save costs and reduce product costs; however, the increase in foreign exchange rates led to higher raw material prices, causing difficulties for production and business operations. As a result, profits decreased.

- The Company invested in the construction of a pharmaceutical manufacturing plant meeting GMP-WHO standards at Quang Minh Industrial Park, Me Linh, Hanoi, and in the existing project "Renovation and expansion of Central Pharmaceutical Factory No.2," with investment capital mainly sourced from loans from the Vietnam Development Bank – Transaction Office No. 1. In 2024, the Bank implemented a policy to write off interest calculated on overdue interest, resulting in reduced loan interest expenses; therefore, in the 4<sup>th</sup> Quarter of 2024, the Company's production and business activities were profitable.

- In 4<sup>th</sup> Quarter 2025, sales revenue decreased compared to the same period last year, leading to a decline in prof.


DP2 respectfully looks forward to receiving the support of the Authorities.

Respectfully!

Recipient:

- As above;

- Archives: Office, Accounting & Finance



**GENERAL DIRECTOR**  
**Pharmacist Le Tien Dung**